LifeMD (NASDAQ:LFMD) Rating Lowered to “Sell” at Wall Street Zen

LifeMD (NASDAQ:LFMD) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other research firms have also commented on LFMD. BTIG Research reaffirmed a “buy” rating and set a $10.00 price objective on shares of LifeMD in a research note on Monday, May 4th. UBS Group reissued a “buy” rating on shares of LifeMD in a research report on Wednesday, May 27th. Weiss Ratings upgraded shares of LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research report on Thursday, May 7th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of LifeMD in a research report on Tuesday, May 26th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.14.

LifeMD Price Performance

Shares of LifeMD stock opened at $4.15 on Friday. LifeMD has a 12-month low of $2.56 and a 12-month high of $12.72. The firm has a market capitalization of $200.69 million, a PE ratio of 83.02 and a beta of 1.99. The stock’s fifty day moving average is $4.55 and its 200-day moving average is $3.97.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). The company had revenue of $50.16 million during the quarter, compared to analyst estimates of $48.84 million. LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. Analysts expect that LifeMD will post -0.37 EPS for the current year.

Institutional Investors Weigh In On LifeMD

A number of institutional investors have recently bought and sold shares of LFMD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in LifeMD by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock valued at $270,000 after buying an additional 2,235 shares during the period. Creative Planning purchased a new stake in shares of LifeMD during the second quarter worth $272,000. JPMorgan Chase & Co. boosted its position in LifeMD by 581.2% during the second quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock valued at $5,619,000 after purchasing an additional 352,004 shares during the last quarter. Legal & General Group Plc grew its stake in LifeMD by 187.4% in the second quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock valued at $138,000 after purchasing an additional 6,614 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of LifeMD by 8.7% during the 2nd quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock worth $730,000 after purchasing an additional 4,281 shares in the last quarter. 35.52% of the stock is currently owned by institutional investors and hedge funds.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.